Systematic Review: Colchicine for the treatment of COVID‐19 – not beneficial for hospitalized patients; inconclusive evidence for the treatment of non-hospitalized patients, “probably slightly reduces the need for hospitalization or death within 28 days compared to placebo”.

Colchicine for the treatment of COVID‐19 – Cochrane Library

Related:

[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.

COLCORONA RCT: Colchicine for community-treated patients with COVID-19 – findings suggest it may lower death and hospital admission rates, but further studies are required.

[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.

Commentary on Twitter

JUST PUBLISHED – Is #colchicine (often used to treat #gout) an effective treatment for people with #COVID19? ➡️ https://t.co/IF1enksFpn New @CochraneHaem systematic review includes evidence from 4 RCTS with 11,525 hospitalised & 4488 non‐hospitalised people.

— The Cochrane Library (@CochraneLibrary) October 18, 2021